Treatment of Carcinoid Syndrome with High Symptom Burden and/or Carcinoid Heart Disease

This protocol applies to patients with aggressive carcinoid syndrome — those presenting with a high symptom burden, tumour progression, extensive hepatic involvement, or carcinoid heart disease. Each of these features can individually signal the need for escalated management beyond standard first-line control.

Clinical Scenario

        Aggressive carcinoid syndrome is defined by one or more of the following: more than four bowel movements per day and/or more than five flushing episodes per day, ongoing tumour progression, hepatic tumour burden exceeding 50% liver involvement, and/or the presence of carcinoid heart disease.
      

Treatment Goals

The primary clinical objectives in this setting are control of refractory CS-associated diarrhoea and reduction in urinary 5-HIAA levels.

Treatment Approach

Management in this aggressive presentation centres on dose-escalation of somatostatin analogue therapy alongside additional targeted treatment modalities. Somatostatin analogue therapy is maintained as a continuous backbone throughout — the complete selection criteria, sequencing, and combination strategy are detailed in the full protocol.

References

DOI: 10.1111/jne.13146

RCS may be divided into either non-aggressive or aggressive, based on symptoms burden (< or ≥ 4 BM/day, and/or < or ≥ 5 flushing episodes/day, respectively) together with disease stability (stable or progressive), hepatic burden (< or ≥ 50% liver involvement), and/or the presence of CHD.

Aggressive CS: more than four bowel movements (BM)/day and/or more than five flushing episodes/day.

SSA should be continued, with their dosage being optimised.

Telotristat ethyl should be added to SSA, where available, for control of RCS-associated diarrhoea.

View source ↗